Revvity, Inc. (RVTY)
NYSE: RVTY · Real-Time Price · USD
105.62
-1.72 (-1.60%)
At close: Mar 28, 2025, 4:00 PM
104.76
-0.86 (-0.81%)
After-hours: Mar 28, 2025, 8:00 PM EDT
Revvity Employees
Revvity had 11,000 employees as of December 29, 2024. The number of employees decreased by 500 or -4.35% compared to the previous year.
Employees
11,000
Change (1Y)
-500
Growth (1Y)
-4.35%
Revenue / Employee
$250,457
Profits / Employee
$24,580
Market Cap
12.69B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 11,000 | -500 | -4.35% |
Dec 31, 2023 | 11,500 | -5,200 | -31.14% |
Dec 31, 2022 | 16,700 | 0 | - |
Dec 31, 2021 | 16,700 | 2,700 | 19.29% |
Dec 31, 2020 | 14,000 | 1,000 | 7.69% |
Dec 31, 2019 | 13,000 | 500 | 4.00% |
Dec 31, 2018 | 12,500 | 1,500 | 13.64% |
Dec 31, 2017 | 11,000 | 3,000 | 37.50% |
Dec 31, 2016 | 8,000 | 0 | - |
Dec 31, 2015 | 8,000 | 300 | 3.90% |
Dec 31, 2014 | 7,700 | 100 | 1.32% |
Dec 31, 2013 | 7,600 | 100 | 1.33% |
Dec 31, 2012 | 7,500 | 300 | 4.17% |
Dec 31, 2011 | 7,200 | 1,000 | 16.13% |
Dec 31, 2010 | 6,200 | -2,000 | -24.39% |
Dec 31, 2009 | 8,200 | 300 | 3.80% |
Dec 31, 2008 | 7,900 | -800 | -9.20% |
Dec 31, 2007 | 8,700 | 200 | 2.35% |
Dec 31, 2006 | 8,500 | 500 | 6.25% |
Dec 31, 2005 | 8,000 | -2,000 | -20.00% |
Dec 31, 2004 | 10,000 | 0 | - |
Dec 31, 2003 | 10,000 | -700 | -6.54% |
Dec 31, 2002 | 10,700 | -100 | -0.93% |
Dec 31, 2001 | 10,800 | -1,700 | -13.60% |
Dec 31, 2000 | 12,500 | 500 | 4.17% |
Dec 31, 1999 | 12,000 | -1,000 | -7.69% |
Dec 31, 1998 | 13,000 | -1,000 | -7.14% |
Dec 31, 1997 | 14,000 | -1,000 | -6.67% |
Dec 31, 1996 | 15,000 | 0 | - |
Dec 31, 1995 | 15,000 | -10,000 | -40.00% |
Dec 31, 1994 | 25,000 | -7,000 | -21.88% |
Dec 31, 1993 | 32,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
RVTY News
- 9 days ago - Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England - Business Wire
- 18 days ago - PerkinElmer Acquires Project Farma, Expanding Its OneSource Professional Services Offering for the Life Sciences Industry - Business Wire
- 26 days ago - Revvity's EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay - Business Wire
- 5 weeks ago - Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group - Business Wire
- 5 weeks ago - Revvity to Present at Upcoming Investor Conferences - Business Wire
- 2 months ago - Revvity, Inc. (RVTY) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending - Reuters
- 2 months ago - Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024 - Business Wire